12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

OX219 neurology data

An open-label pivotal trial in about 55 healthy volunteers showed that OX219 had comparable bioavailability to Suboxone Buprenorphine/Naloxone based on mean peak (Cmax) and area under the curve (AUC) plasma concentrations. Orexo said that upon completion of this trial, it has generated all pivotal clinical data necessary. In...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >